{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"31.2","value":"11.8"},{"comment":"Not calculated due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Not calculated. By design, all patients in this cohort had surgery shortly after initiation of dordaviprone (ONC201) with no preceding post-baseline assessment; hence, all patients are censored for PFS at baseline.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG003","lowerLimit":"4.6","upperLimit":"29.8","value":"14.5"},{"comment":"Not calculated due to insufficient number of participants with events.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG005","lowerLimit":"0.7","upperLimit":"46.5","value":"14.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"7"}],"units":"Participants"}],"description":"Progression-free survival rate at 6 months was defined as the percentage of patients who exhibit progression-free survival for \\>6 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with histologically confirmed WHO Grade IV glioblastoma with any number of recurrences.\n\nPatients received 625 mg oral ONC201 once every 3 weeks.","id":"OG000","title":"Arm A"},{"description":"Patients with first recurrence of histologically confirmed WHO Grade IV glioma.\n\nPatients received 625 mg oral ONC201 once every week (Days 1, 8, and 15 of each cycle).","id":"OG001","title":"Arm B"},{"description":"Patients with clinical and/or radiographic evidence of first recurrence of histologically confirmed WHO Grade IV glioblastoma and were eligible for salvage surgical resection.\n\nPatients received 625 mg oral ONC201 once weekly (Days 1, 8 and 15 of each cycle). Surgical resection was performed approximately 24 hours after at least the second dose of ONC201.","id":"OG002","title":"Arm C"},{"description":"Patients with confirmed WHO Grade IV glioma with H3 K27M mutation (any number of recurrences were allowed).\n\nPatients received 625 mg oral ONC201 once weekly (Days 1, 8, and 15 of each cycle).","id":"OG003","title":"Arm D"},{"description":"Patients with clinical and/or radiographic evidence of midline glioma (recurrent disease was not required) and were eligible for salvage surgical resection.\n\nPatients received 625 mg oral ONC201 once weekly (Days 1, 8 and 15 of each cycle). Surgical resection was performed approximately 24 hours after at least the second dose of ONC201.","id":"OG004","title":"Arm E"},{"description":"Patients with diffuse midline glioma involving the brainstem, thalamus, or spinal cord, without H3 K27M mutation or with unknown H3 mutation status.\n\nPatients received 625 mg oral ONC201 once weekly (Days 1, 8, and 15 of each cycle).","id":"OG005","title":"Arm F"}],"paramType":"NUMBER","populationDescription":"Note: In Arm B, one participant with recurrent H3 K27M-mutant glioblastoma and non-measurable disease experienced complete regression of enhancing lesions for \\>1.5 years was censored from analysis due to use of anastrozole at baseline and throughout the study.","reportingStatus":"POSTED","timeFrame":"Progression-free survival assessments were conducted 6 months following treatment initiation.","title":"Percent of Patients With Probability of Progression-Free Survival at 6 Months","type":"PRIMARY","unitOfMeasure":"percentage of patients"}